BI-836880

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-836880

Drug Alias NameBI-836880

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAngiopoietin-2 inhibitorsVascular endothelial growth factor A inhibitors

TargetsAngiopoietin-2Vascular endothelial growth factor A

Therapy Area/IndicationsWet age-related macular degenerationNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermanyUnited Kingdom +[5]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAblynx Nv

China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg

Inactive CompaniesN/A

Active IndicationsWet age-related macular degeneration

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A